Skip to main content

vTv Therapeutics Inc. (VTVT)

NASDAQ: VTVT · IEX Real-Time Price · USD
1.43
+0.03 (2.14%)
After-hours:Oct 22, 2021 7:59 PM EDT
1.40
-0.04 (-2.78%)
At close: Oct 22, 4:00 PM
Market Cap116.60M
Revenue (ttm)7.40M
Net Income (ttm)-5.26M
Shares Out81.11M
EPS (ttm)-0.10
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume723,573
Open1.42
Previous Close1.44
Day's Range1.39 - 1.43
52-Week Range1.39 - 4.75
Beta-1.65
AnalystsBuy
Price Target6.75 (+382.1%)
Est. Earnings DateNov 4, 2021

About VTVT

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates to fill unmet medical needs. The company is developing TTP399, an orally administered, small molecule, liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant PDE4 inhibitor that addresses inflammatory diseases. It is also involved in the clinical development of other programs, including a small molecule GLP-1r agonist; the PD...

IndustryBiotechnology
IPO DateJul 30, 2015
CEOStephen Holcombe
Employees25
Stock ExchangeNASDAQ
Ticker SymbolVTVT
Full Company Profile

Financial Performance

In 2020, VTVT's revenue was $6.41 million, an increase of 132.05% compared to the previous year's $2.76 million. Losses were -$8.50 million, -34.84% less than in 2019.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for VTVT stock is "Buy." The 12-month stock price forecast is 6.75, which is an increase of 382.14% from the latest price.

Price Target
$6.75
(382.14% upside)
Analyst Consensus: Buy

News

vTv Therapeutics Announces Deepa Prasad as New President and CEO

HIGH POINT, N.C., Oct. 20, 2021 /PRNewswire/ -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 di...

3 days ago - PRNewsWire

vTv Therapeutics Announces Positive Results from Mechanistic Study Indicating No Increased Risk of Ketoacidosis with ...

Study achieved primary endpoint of non-inferiority on measurement of key blood ketone levels

1 week ago - GlobeNewsWire

vTv Therapeutics Stock Gains As Psoriasis Candidate Shows Favorable Safety Profile

​​​​​vTv Therapeutics Inc (NASDAQ: VTVT) announced the results of a multiple ascending dose study evaluating HPP737 in healthy adults. HPP737 is an orally administered phosphodiesterase type 4 (PDE4) in...

4 weeks ago - Benzinga

vTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inh...

HPP737 exhibited favorable safety and tolerability profile, with no dose limiting gastrointestinal side effects

4 weeks ago - GlobeNewsWire

7 Penny Stocks Waiting on The FDA for Rocket Fuel

News of regulatory approval or progress would really help to move the needle for these seven biotech penny stocks. The post 7 Penny Stocks Waiting on The FDA for Rocket Fuel appeared first on InvestorPl...

1 month ago - InvestorPlace

Down 16.1% in 4 Weeks, Here's Why vTv Therapeutics (VTVT) Looks Ripe for a Turnaround

vTv Therapeutics (VTVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in rev...

2 months ago - Zacks Investment Research

VTv Therapeutics (VTVT) Reports Q2 Loss, Lags Revenue Estimates

vTv Therapeutics (VTVT) delivered earnings and revenue surprises of 85.71% and -99.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

vTv Therapeutics Announces 2021 Second Quarter Financial Results and Provides Corporate Update

HIGH POINT, N.C., Aug. 04, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter ended June 30, 2021, and provided an update on the progres...

2 months ago - GlobeNewsWire

3 Biopharma Penny Stocks That Could be Millionaire Makers

These three biotech penny stocks all have developed drugs that have shown strong indications of success. The post 3 Biopharma Penny Stocks That Could be Millionaire Makers appeared first on InvestorPlace.

Other symbols:CLSNZSAN
3 months ago - InvestorPlace

vTv Therapeutics to Participate at the 6th World Psoriasis & Psoriatic Arthritis Conference with Poster Presentation ...

HIGH POINT, N.C., June 29, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type...

3 months ago - GlobeNewsWire

Buying Biotech Penny Stocks? 3 Trading Tips And 7 To Watch

Are biotech penny stocks worth it? Here's 3 tips for investing and 7 small-caps to watch The post Buying Biotech Penny Stocks?

Other symbols:CTXRJAGXOCGNOPKZSAN
3 months ago - PennyStocks

Top 10 Biotech Penny Stocks to Watch in July 2021

Are these the best biotech penny stocks to watch next month? Here's 5 more for your list The post Top 10 Biotech Penny Stocks to Watch in July 2021 appeared first on Penny Stocks to Buy, Picks, News and...

Other symbols:ADILMNOVOPK
4 months ago - PennyStocks

Why Moderna, Bio-Path Holdings And vTv Therapeutics Are Moving Today

Moderna, Inc. (NASDAQ: MRNA), Bio-Path Holdings, Inc. (NASDAQ: BPTH) and vTv Therapeutics Inc. (NASDAQ: VTVT) are among the biggest biotech movers Tuesday. Moderna Gains On Additional EU Orders: Moderna...

Other symbols:BPTHMRNA
4 months ago - Benzinga

vTv Therapeutics Shares Jump On Out-Licensing Agreement For Azeliragon In Cancer Settings

Privately-held Cantex Pharmaceuticals Inc has entered into a licensing agreement with vTv Therapeutics Inc (NASDAQ: VTVT) to develop and commercialize vTv's azeliragon. Under the terms of the agreement,...

4 months ago - Benzinga

vTv Therapeutics and Cantex Pharmaceuticals Announce Strategic Licensing Agreement for Development and Commercializat...

HIGH POINT, N.C. and WESTON, Fla., June 22, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (“vTv”, Nasdaq:VTVT) and Cantex Pharmaceuticals, Inc. (“Cantex”) today announced that they have entered into a ...

4 months ago - GlobeNewsWire

What Are Penny Stocks? 4 to Buy [Or Sell] In 2021

Wondering what penny stocks are? Here's your answer and 4 to watch The post What Are Penny Stocks?

Other symbols:AMSTORPH
4 months ago - PennyStocks

VTv Therapeutics (VTVT) Reports Q1 Loss, Tops Revenue Estimates

vTv Therapeutics (VTVT) delivered earnings and revenue surprises of -50.00% and 23.38%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

vTv Therapeutics Announces 2021 First Quarter Financial Results and Provides Corporate Update

Awarded Breakthrough Therapy designation for TTP399 for the treatment of type 1 diabetes

5 months ago - GlobeNewsWire

4 Up-and-Coming Stocks to Buy in Shifting Sectors

vTv Therapeutics, Arrival, PubMatic, and Schrodinger are four up-and-coming stocks to buy. All four are benefiting from rapidly shifting trends.

Other symbols:ARVLPUBMSDGR
5 months ago - InvestorPlace

vTv Therapeutics (VTVT) Gets Breakthrough Tag for Diabetes Drug

The FDA bestows a Breakthrough Therapy designation to vTv Therapeutics' (VTVT) TTP399 as an adjunctive therapy to insulin for treating type I diabetes. Shares rise.

6 months ago - Zacks Investment Research

VTVT Stock: The FDA News Sending vTv Therapeutics Soaring Today

Today, VTVT stock is on the move as investors price in a key announcement from the FDA designating a leading drug a breakthrough therapy. The post VTVT Stock: The FDA News Sending vTv Therapeutics Soari...

6 months ago - InvestorPlace

vTv Therapeutics Receives FDA Breakthrough Therapy Designation for TTP399 for the Treatment of Type 1 Diabetes

Designation offers potential for expedited development pathway and reinforces TTP399's potential to provide a substantial clinical benefit Designation offers potential for expedited development pathway ...

6 months ago - GlobeNewsWire

TTP399 SimpliciT-1 Study Results to be presented at a scientific symposium in celebration of the 100th anniversary of...

HIGH POINT, N.C., April 12, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for typ...

6 months ago - GlobeNewsWire

vTv Therapeutics Announces Issuance of U.S. Patent Covering Methods of Treatment Using TTP399

Claims cover methods of reducing HbA1c and the incidence of hypoglycemia using TTP399 in patients with type 1 diabetes Claims cover methods of reducing HbA1c and the incidence of hypoglycemia using TTP3...

7 months ago - GlobeNewsWire

vTv Therapeutics Announces Initiation of Study Evaluating TTP399's Potential to Reduce Risk of Diabetic Ketoacidosis ...

HIGH POINT, N.C., March 18, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for typ...

7 months ago - GlobeNewsWire